From MarketBeat:

COMPASS Pathways plc (NASDAQ:CMPS) experienced a substantial increase in short interest in December, with a total of 4,350,000 shares, up 12.7% from November. The short-interest ratio is 8.3 days based on 526,000 shares of average daily volume.

Institutional investors have shown interest in COMPASS Pathways. UBS Group AG, Quantbot Technologies LP, Advisor Group Holdings Inc., and others increased their holdings in the company, now owning 18.13% of the stock.

Deutsche Bank Aktiengesellschaft gave a “buy” rating and a $16.00 price target for COMPASS Pathways. The stock has a consensus rating of “Buy” and a consensus price target of $44.00.

On December 15th, CMPS stock traded down to $8.75 with a market capitalization of $541.63 million, a PE ratio of -3.38, and a beta of 2.58. The company’s 52-week range is $5.01 to $11.15.

COMPASS Pathways last reported an earnings-per-share of ($0.67) for its quarterly earnings, missing consensus estimates by ($0.17). Current expectations are for -2.24 EPS for the current fiscal year.

COMPASS Pathways plc develops COMP360, a psilocybin therapy that is currently in Phase III clinical trials for treating treatment-resistant depression, as well as in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.



Read more: COMPASS Pathways plc (NASDAQ:CMPS) Sees Significant Growth in Short Interest